PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more
PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed... read more
PEABODY, Mass., June 3, 2021 -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more